National Comprehensive Cancer Network investigational drug service consensus recommendations
Am J Health Syst Pharm
.
2022 Mar 7;79(6):486-491.
doi: 10.1093/ajhp/zxab455.
Authors
Sapna Amin
1
,
Stephen Polley
2
,
Sean DeFrates
3
,
Heidi D Finnes
4
,
Katharine Kinsman
5
,
Elyse MacDonald
6
,
Latanya Dean
7
,
Lorri DeWitt
8
,
Caroline Harvey
9
,
Susan Johnston
10
,
Tzewah Vivian Leung
11
,
Emily A Moll
12
,
Gerald P O'Neill
13
,
Kimberly A Redic
12
,
Sharon F Park
14
Affiliations
1
Division of Pharmacy, MD Anderson Cancer Center, Houston, TX, USA.
2
The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
3
Department of Pharmacy, Northwestern Memorial Hospital, Chicago, IL, USA.
4
Department of Pharmacy, Mayo Clinic, Cancer Center, Rochester, MN, USA.
5
University of Washington Medical Center/ Seattle Cancer Care Alliance, Seattle, WA, USA.
6
Department of Pharmacy Services, Stanford Health Care, Palo Alto, CA, USA.
7
Stanford Health Care, Department of Pharmacy Services, Palo Alto, CA, USA.
8
Barnes Jewish Hospital Investigational Drug Service, St. Louis, MO, USA.
9
Dana-Farber Cancer Institute, Boston, MA, USA.
10
UW Health - University of Wisconsin, Madison, WI, USA.
11
Department of Pharmacy, University of Pennsylvania, Philadelphia, PA, USA.
12
Department of Pharmacy Services, Michigan Medicine, Ann Arbor, MI, USA.
13
Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
14
National Comprehensive Cancer Network, Plymouth Meeting, PA, USA.
PMID:
34849539
DOI:
10.1093/ajhp/zxab455
No abstract available
Keywords:
consensus; drugs; investigational; pharmaceutical services; pharmacy; policy; research.
MeSH terms
Consensus
Drugs, Investigational
Humans
Neoplasms* / drug therapy
Pharmacy Service, Hospital*
Substances
Drugs, Investigational